SG11202006459XA - Proteinaceous molecules and uses therefor - Google Patents

Proteinaceous molecules and uses therefor

Info

Publication number
SG11202006459XA
SG11202006459XA SG11202006459XA SG11202006459XA SG11202006459XA SG 11202006459X A SG11202006459X A SG 11202006459XA SG 11202006459X A SG11202006459X A SG 11202006459XA SG 11202006459X A SG11202006459X A SG 11202006459XA SG 11202006459X A SG11202006459X A SG 11202006459XA
Authority
SG
Singapore
Prior art keywords
uses therefor
proteinaceous molecules
proteinaceous
molecules
therefor
Prior art date
Application number
SG11202006459XA
Inventor
Sudha Rao
Peter Milburn
Original Assignee
Epiaxis Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2018900108A external-priority patent/AU2018900108A0/en
Application filed by Epiaxis Therapeutics Pty Ltd filed Critical Epiaxis Therapeutics Pty Ltd
Publication of SG11202006459XA publication Critical patent/SG11202006459XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70532—B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11202006459XA 2018-01-15 2019-01-15 Proteinaceous molecules and uses therefor SG11202006459XA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2018900108A AU2018900108A0 (en) 2018-01-15 Proteinaceous molecules and uses therefor
PCT/AU2019/050024 WO2019136531A1 (en) 2018-01-15 2019-01-15 Proteinaceous molecules and uses therefor

Publications (1)

Publication Number Publication Date
SG11202006459XA true SG11202006459XA (en) 2020-08-28

Family

ID=67218182

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202006459XA SG11202006459XA (en) 2018-01-15 2019-01-15 Proteinaceous molecules and uses therefor

Country Status (8)

Country Link
US (1) US20200339691A1 (en)
EP (1) EP3740496A4 (en)
JP (1) JP2021510538A (en)
CN (1) CN111936509A (en)
AU (1) AU2019207534B2 (en)
CA (1) CA3087761A1 (en)
SG (1) SG11202006459XA (en)
WO (1) WO2019136531A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202006441SA (en) * 2018-01-15 2020-08-28 Epiaxis Therapeutics Pty Ltd Agents and methods for predicting response to therapy
EP4025610A4 (en) * 2019-09-03 2023-08-02 The Council of the Queensland Institute of Medical Research Methods and agents for determining patient status
CN111411082B (en) * 2020-03-26 2022-04-01 中山大学孙逸仙纪念医院 Culture medium for culturing CD90posi cells and culture method thereof
AU2022209878A1 (en) * 2021-01-19 2023-09-07 The Council Of The Queensland Institute Of Medical Research Novel bicyclic peptides
CN112759626B (en) * 2021-02-03 2022-10-14 安徽大学 Nuclear localization signal peptide and sequence and application thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4511173B2 (en) * 2001-08-24 2010-07-28 マイジェニックス インコーポレイテッド Antibacterial and anti-inflammatory peptides
WO2008021542A2 (en) * 2006-08-17 2008-02-21 Cell Signaling Technology, Inc. Lysine acteylation sites
JP2013512251A (en) * 2009-11-24 2013-04-11 アンプリミューン、インコーポレーテッド Simultaneous inhibition of PD-L1 / PD-L2
JP6810396B2 (en) * 2015-04-30 2021-01-06 国立大学法人京都大学 Method for predicting therapeutic effect of PD-1 / PD-L1 inhibitor using PD-L1 (CD274) abnormality as an index
WO2017220602A1 (en) * 2016-06-21 2017-12-28 Herlev Hospital Pdl1 peptides for use in cancer vaccines

Also Published As

Publication number Publication date
CA3087761A1 (en) 2019-07-18
AU2019207534B2 (en) 2022-06-09
CN111936509A (en) 2020-11-13
JP2021510538A (en) 2021-04-30
EP3740496A4 (en) 2021-12-08
AU2019207534A1 (en) 2020-07-23
US20200339691A1 (en) 2020-10-29
WO2019136531A1 (en) 2019-07-18
EP3740496A1 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
EP3684365A4 (en) Protein degraders and uses thereof
EP3625358A4 (en) Biomarkers and uses thereof
IL281568A (en) Collagen-localized immunomodulatory molecules and methods thereof
EP3331549A4 (en) Improved microbe-binding molecules and uses thereof
GB202006164D0 (en) Recombinant collagen and eslastin molecules and uses thereof
SG11202006459XA (en) Proteinaceous molecules and uses therefor
ZA201900209B (en) Novel natural protein and application thereof
IL282362A (en) Intein proteins and uses thereof
IL278832A (en) Optimized gp41-binding molecules and uses thereof
EP3312273A4 (en) Protein degradation inducing tag and usage thereof
EP3515449A4 (en) Chromobox protein inhibitors and uses thereof
GB201812561D0 (en) Biomarkers and uses thereof
EP3630732A4 (en) Method and molecules
GB201707248D0 (en) Modified complement proteins and uses thereof
GB201806042D0 (en) Biomarkers and uses thereof
IL284781A (en) Lilrb3-binding molecules and uses therefor
EP3387007A4 (en) Proteinaceous molecules and methods of use
IL280369A (en) New myokines and uses thereof
EP3976630A4 (en) Actrii-binding proteins and uses thereof
GB201819125D0 (en) Biomarkers and uses thereof
EP3411061A4 (en) Proteinaceous compounds and uses therefor
HUP1700012A2 (en) Novel proteins and use thereof
AU2018900108A0 (en) Proteinaceous molecules and uses therefor
IL285585A (en) Fcmr-binding molecules and uses thereof
EP4081255A4 (en) Anti-csf1r molecules and use thereof